Pharmaceutical companies are investing in therapies that target proteins for degradation, with trials ongoing for cancer, autoimmune diseases and neurological disorders. Pharmaceutical companies are investing in therapies that target proteins for degradation, with trials ongoing for cancer, autoimmune diseases and neurological disorders.
Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser . In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.
Despite billions of dollars in research and development, some proteins remain stubbornly undruggable. Some lack an active site to inhibit or agonize, whereas others are inaccessible in the dense chemical ‘soup’ of the nucleus and cytoplasm. In the past, if drug developers could not find a druggable target, they were simply out of luck. But now, previously undruggable proteins can be targeted for degradation via proteolysis.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Jefferies says buy this pharmaceutical play, sees more than 100% upside from hereThis pharmaceutical company's recent drug developments could spell more gains ahead, according to Jefferies.
Read more »
Is RFK Jr. Just What The Doctor Ordered? The 5 Critical First SignsSteve Brozak is President of WBB Securities, LLC, an investment bank and research firm that specializes in the biotechnology, specialty pharmaceutical and medical device sectors.
Read more »
New FDA rules target those ubiquitous TV drug commercialsThe agency’s new guidelines are created to eliminate pharmaceutical company practices that minimize or distract consumers from knowing risk information about drugs.
Read more »
Amgen, Merck stocks dive as Trump picks anti-vaxxer RFK Jr. to lead US healthcarePharmaceutical stocks are tripping over themselves to sell off on Friday after President-elect Donald Trump announced Robert F.
Read more »
RFK Jr. is Trump's pick to lead HHS — here's what he could do with that powerTrump’s selection is sounding the alarm in the public health community and leaving the biotech and pharmaceutical industries cautious of changes to…
Read more »
Medicare May Soon Cover Ozempic, Wegovy Under New Biden ProposalIf the proposal is finalized, it could set the stage for a showdown between the pharmaceutical industry and the Trump administration.
Read more »